LncRNA PCAT19 induced by SP1 and acted as oncogene in gastric cancer competitively binding to miR429 and upregulating DHX9

Xiao, Lei; Yuan, Weijie; Huang, Changhao; Luo, Qingqing; Xiao, Runsha; Chen, Zihua

doi:10.7150/jca.61961

Cited by 9 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[25] Moreover, some studies showed that PCAT19 is implicated in PCa cell growth and tumor progression. [26][27][28] The nature of TME in the evolution of cancer has changed our understanding of cancer development. [29,30] A wide variety of immune and non-immune cells within the TME infrastructure, together with the factors that they secrete, cooperate to create a chronic inflammatory, immunosuppressive, and protumoral environment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer

Jin

Tang

et al. 2023

Medicine

View full text Add to dashboard Cite

Bladder cancer (BC) is a frequently diagnosed cancer with high mortality. Male patients have a higher risk of developing BC than female patients. As a type of caspase-independent cell death, necroptosis plays a significant role in the occurrence and progression of BC. The aberrant function of long non-coding RNAs (lncRNAs) plays an indispensable role in GI. However, the relationship between lncRNA and necroptosis in male patients with BC remains unclear. The clinical information and RNA-sequencing profiles of all BC patients were retrieved from The Cancer Genome Atlas Program. A total of 300 male participants were selected for the study. We conducted to identify the necroptosis-related lncRNAs (NRLs) by Pearson correlation analysis. Subsequently, least absolute shrinkage and selection operator Cox regression were conducted to establish a risk signature with overall survival-related NRLs in the training set and to validate it in the testing set. Finally, we verified the effectiveness of the 15-NRLs signature in prognostic prediction and therapy via survival analysis, receiver operating characteristic curve analysis, and Cox regression. Furthermore, we analyzed the correlation between the signature risk score and pathway enrichment analysis, immune cell infiltration, anticancer drug sensitivity, and somatic gene mutations. We developed 15-NRLs (AC009974.1, AC140118.2, LINC00323, LINC02872, PCAT19, AC017104.1, AC134312.5, AC147067.2, AL139351.1, AL355922.1, LINC00844, AC069503.1, AP003721.1, DUBR, LINC02863) signature, and divided patients into a high-risk group and low-risk group through the median risk score. Kaplan–Meier and receiver operating characteristic curves showed that the prognosis prediction had satisfactory accuracy. Cox regression analysis indicated that the 15-NRLs signature was a risk factor independent of various clinical parameters. Additionally, immune cell infiltration, half-maximal inhibitory concentration, and somatic gene mutations differed significantly among different risk subsets, implying that the signature could assess the clinical efficacy of chemotherapy and immunotherapy. This 15-NRLs risk signature may be helpful in assessing the prognosis and molecular features of male patients with BC and improve treatment modalities, thus can be further applied clinically.

show abstract

Section: Discussionmentioning

confidence: 99%

“…[25] Moreover, some studies showed that PCAT19 is implicated in PCa cell growth and tumor progression. [26–28]…”

Section: Discussionmentioning

confidence: 99%

A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer

Jin

Tang

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…We also performed lncRNA microarray analysis in 5 paired gastric cancer tissues of our institution to detect the lncRNA expression profile. We have already described the processing and analysis of data in the previous study [ 21 ].…”

Section: Methodsmentioning

confidence: 99%

DHRS4-AS1 regulate gastric cancer apoptosis and cell proliferation by destabilizing DHX9 and inhibited the association between DHX9 and ILF3

Xiao,

zhang,

Luo

et al. 2023

Cancer Cell Int

Self Cite

View full text Add to dashboard Cite

Gastric cancer (GC) causes millions of cancer-related deaths due to anti-apoptosis and rapid proliferation. However, the molecular mechanisms underlying GC cell proliferation and anti-apoptosis remain unclear. The expression levels of DHRS4-AS1 in GC were analyzed based on GEO database and recruited GC patients in our institution. We found that DHRS4-AS1 was significantly downregulated in GC. The expression of DHRS4-AS1 in GC tissues showed a significant correlation with tumor size, advanced pathological stage, and vascular invasion. Moreover, DHRS4-AS1 levels in GC tissues were significantly associated with prognosis. DHRS4-AS1 markedly inhibited GC cell proliferation and promotes apoptosis in vitro and in vivo assays. Mechanically, We found that DHRS4-AS1 bound to pro-oncogenic DHX9 (DExH-box helicase 9) and recruit the E3 ligase MDM2 that contributed to DHX9 degradation. We also confirmed that DHRS4-AS1 inhibited DHX9-mediated cell proliferation and promotes apoptosis. Furthermore, we found DHX9 interact with ILF3 (Interleukin enhancer Binding Factor 3) and activate NF-kB Signaling in a ILF3-dependent Manner. Moreover, DHRS4-AS1 can also inhibit the association between DHX9 and ILF3 thereby interfered the activation of the signaling pathway. Our results reveal new insights into mechanisms underlying GC progression and indicate that LncRNA DHRS4-AS1 could be a future therapeutic target and a biomarker for GC diagnosis.

show abstract

“…LncRNAs have been found to be involved in a variety of biological processes, can act as oncogenes or tumor suppressors, and are associated with various aspects of cancer, including tumorigenesis, metastasis, and treatment resistance [15][16][17][18][19]. The aberrant expression patterns of lncRNAs in GI cancers have been linked to clinical outcomes, making them promising tumor markers and potential therapeutic targets [11,[20][21][22][23][24][25][26].…”

Section: Ivyspringmentioning

confidence: 99%

LncRNA-MUF: A Novel Oncogenic Star with Potential as a Biological Marker and Therapeutic Target for Gastrointestinal Malignancies

Wang,

Zhang

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers pose a significant global health challenge, characterized by a high incidence and poor prognosis. The delayed detection and occurrence of metastasis contribute to the overall low survival rates associated with these cancers. Therefore, there is an urgent need to identify novel molecular targets for effective GI cancer treatment. Recent research has shed light on the potential of long non-coding RNAs (lncRNAs) as promising targets in cancer therapy, given their strong association with carcinogenesis and profound impact on tumor development. Among these lncRNAs, lncRNA-MUF, also known as LINC00941, has emerged as a key player in oncogenic regulation, specifically implicated in the progression of various GI cancers, including esophageal, gastric, colorectal, hepatic, and pancreatic cancer. This review aims to provide an updated and focused analysis of the regulatory roles of LINC00941 in the initiation and progression of GI cancer. Our objective is to unravel the underlying molecular mechanisms through which LINC00941 influences GI cancer phenotypes both in vivo and in vitro, with a special emphasis on the key molecules and signaling pathways involved. Additionally, LINC00941 has demonstrated clinical significance in terms of clinical pathology, prognosis, and diagnosis in GI tumors, further reinforcing its potential as a novel therapeutic target.

show abstract

LncRNA PCAT19 induced by SP1 and acted as oncogene in gastric cancer competitively binding to miR429 and upregulating DHX9

Cited by 9 publications

References 25 publications

A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer

A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer

DHRS4-AS1 regulate gastric cancer apoptosis and cell proliferation by destabilizing DHX9 and inhibited the association between DHX9 and ILF3

LncRNA-MUF: A Novel Oncogenic Star with Potential as a Biological Marker and Therapeutic Target for Gastrointestinal Malignancies

Contact Info

Product

Resources

About